Pioneering precision epigenetic medicines

We are hiring passionate, talented moonwalkers. See our open roles.

Our science

By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed.

First in the field

Moonwalk is the first company to couple an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases.

Engineering the epigenome

Moonwalk technology brings the most advanced AI prediction of epigenetic targets, and the broadest set of epigenetic engineering tools.

Moonwalk’s focus

Moonwalk’s focus on epigenetic engineering leverages comprehensive read-and-write technologies to develop potentially curative therapies for diseases at the root cause.

Moonwalk's Team

Alex Aravanis, MD, PhD

Co-Founder, CEO

Sid Bagaria, MPhil

Principal Scientist, Bioinformatics ML/AI

Alex Campbell, MS

Scientist II, R&D

Elaine Cheung, MS

Chief Business Officer

Jen Fleischer, MS, JD

Head of Intellectual Property

Larry Garrido

Director of Facilities & Lab Operations

Sam Gross, PhD

Head of Bioinformatics & ML/AI

Arash Jamshidi, PhD

Co-Founder, President & CTO

Rigel Kishton, PhD

Head of Immunology Research

John Liles, PhD

VP Biology & Translational Science

Pedro Mendez

Director, Research

Sanjay Pandey, PhD

Director, Translational Science

Justin Valley, PhD

Co-Founder, Chief Platform Officer

Jeff Weng

Associate Scientist

Feng Zhang, PhD

Scientific Co-Founder

Liyang Zhang, PhD

Associate Director, R&D

Moonwalk News

October 21, 2024

Moonwalk Biosciences to Present New Epigenetic Data at ObesityWeek® 2024 and The Liver Meeting® 2024

August 19, 2024

Moonwalk Biosciences Appoints VP of Biology and Translational Science and Announces Formation of Cardiometabolic Advisory Board

Investors